# A Study of EH002 Gene Therapy for Otoferlin Gene Mutation-mediated Hearing Loss

> **NCT06722170** · NA · RECRUITING · sponsor: **Yilai Shu** · enrollment: 24 (estimated)

## Conditions studied

- DFNB9
- Congenital Hearing Loss
- Hearing Loss, Sensorineural

## Interventions

- **GENETIC:** EH002 administration

## Key facts

- **NCT ID:** NCT06722170
- **Lead sponsor:** Yilai Shu
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-22
- **Primary completion:** 2027-11
- **Final completion:** 2029-11
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2025-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06722170

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06722170, "A Study of EH002 Gene Therapy for Otoferlin Gene Mutation-mediated Hearing Loss". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06722170. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*